News & Updates

In the treatment of patients with COVID-19, administering remdesivir within 5 days of symptom onset appears to reduce the risk of progression to severe disease, as shown in a study.

In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.

Nonsmall cell lung cancer (NSCLC) with mutations in the KRAS gene show a unique genetic and clinical profile in Asian patients relative to Western counterparts, according to a recent study.

Treatment with the selective serotonin reuptake inhibitor fluvoxamine may prevent hospitalization in outpatients presenting with symptoms of COVID-19 who have a high risk for disease progression, according to results of the TOGETHER trial.

Bacteraemic pneumococcal community-acquired pneumonia is associated with higher disease severity and frequent intensive care unit admission, as reported in a study. However, SARS-CoV-2-related pneumonia poses a greater mortality risk.

Among patients with Mycobacterium avium complex pulmonary disease, the risk of chronic pulmonary aspergillosis development and mortality is high in the presence of emphysema, according to a study.

Among patients with COVID-19 infection, those who smoke are at higher risk of developing complications compared with those who do not smoke, according to a study from Malaysia.